Prostate cancer Board decisions

The Veteran's appeal is being remanded for further examination and analysis to determine if his service-connected disabilities render him unemployable.

The Board denied the Veteran's claim for an effective date prior to November 8, 2001, for nonservice-connected pension benefits.

The Veteran's prostate cancer was not incurred in or aggravated by active service, and the Board denied his claim for service connection.

The Board denied an earlier effective date for special monthly compensation based on loss of use of a creative organ, finding that the claim arose from an original service connection grant and not a claim for an increase. The effective date is set at May 27, 2004.

The Veteran's prostate cancer, initially manifested years after service, is not shown by the preponderance of the competent clinical evidence to be related to his active service.

The Veteran's claims for service connection for diabetes mellitus, prostate cancer, impotence, peripheral neuropathy of both upper and lower extremities, and depression have all been denied as secondary to herbicide exposure. The evidence does not support a finding that the Veteran was exposed to Agent Orange in Panama.

The Board found that the evidence does not support a finding of service connection for erectile dysfunction as secondary to service-connected prostate cancer.

The Veteran died of complications due to cirrhosis of the liver, which is not service-connected. The Board finds that his prostate and bladder cancer did not cause or contribute substantially to his death.

The Board has remanded the case due to uncertainty regarding the Veteran's service in Vietnam, which could affect his claim for service connection based on herbicide exposure. The Veteran is presumed exposed to Agent Orange and may be entitled to service connection for prostate cancer and peripheral neuropathy if these conditions are associated with such exposure.

The Board denied service connection for anxiety disorder, anemia, prostate cancer (claimed as prostate problem), a condition manifested by dizziness, and a condition manifested by easy fatigability. The Veteran did not have any current psychiatric disability that could be linked to his military service.

The Veteran's appeal has been withdrawn due to his statement that he is seeking service connection for prostate cancer, not prostatitis.

The Veteran's service-connected conditions, including prostate cancer residuals, PTSD, and erectile dysfunction, are preventing him from obtaining or maintaining substantially gainful employment. The case is being remanded for further examination and development.

The Board found that the Veteran's prostate cancer is not related to his service, including exposure to ionizing radiation during active duty. The claim for service connection was denied.

The Veteran's prostate cancer residuals, resulting in urinary incontinence and frequent urination, meet the criteria for a 60 percent rating since August 1, 2005.

The Board has granted service connection for prostate cancer as secondary to Agent Orange exposure, based on the Veteran's documented trips into Vietnam and his current diagnosis of prostate cancer.

The Board denied the Veteran's claims for service connection for prostate cancer and colon cancer, finding that there was no evidence of exposure to ionizing radiation during service or a nexus between the cancers and service.

The Board has remanded the case due to incomplete records, and the Veteran's claim for service connection for prostate cancer as a result of exposure to ionizing radiation and herbicides is pending.

The Veteran's GERD is aggravated by his service-connected PTSD, and the criteria for service connection by aggravation have been met. The issue of prostate cancer has been remanded due to the need for special development procedures under VA regulations.

The Veteran's claims of service connection for various disabilities, including right and left shoulder disabilities, back disability, hypertension, and left foot disability have been reopened. An initial compensable evaluation (10%) has been assigned for degenerative joint disease of the right great toe.

The Board has remanded the case for additional development, including obtaining a revised dose estimate from DTRA based on the location of the appellant's duty station.